Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James McDonough

Psychiatry Longwood, FL Medical Doctor

NPI 1063468700 CMS profile 3451

455 W Warren Ave, Longwood, FL 32750

Open in the dashboard

General payments

$4,794

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$151,240 paid to institutions, not to them · program year 2019

Through program year 2025, James McDonough of Longwood, FL is reported in the CMS Open Payments database as having received $4,794 across 237 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $151,240 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,029 48
2024 General $1,099 40
2023 General $625 33
2022 General $600 32
2021 General $592 34
2020 General $388 22
2019 General $461 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James McDonough
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to James McDonough were reported at $1,029. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year James McDonough Psychiatry median Middle half National median
2019 $461 $184 $59–$605 $163
2020 $388 $119 $36–$372 $114
2021 $592 $143 $43–$576 $132
2022 $600 $153 $50–$590 $149
2023 $625 $170 $56–$651 $160
2024 $1,099 $179 $57–$673 $164
2025 $1,029 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $653 32 payments
  2. Otsuka America Pharmaceutical, Inc. $501 28 payments
  3. Supernus Pharmaceuticals, Inc. $371 6 payments
  4. Neurocrine Biosciences, Inc. $360 14 payments
  5. Lundbeck LLC $341 17 payments
  6. AbbVie, Inc. $341 18 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $320 18 payments
  8. Corium, Inc. $217 13 payments
  9. ITI, Inc. $215 10 payments
  10. Tris Pharma Inc $198 12 payments
  11. Other $1,277 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,747 236 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. SPRAVATO $644 31 payments
  2. REXULTI Psychiatry $462 26 payments
  3. INGREZZA $343 13 payments
  4. VRAYLAR $341 18 payments
  5. Qelbree $322 3 payments
  6. REXULTI Psychiatry $275 13 payments
  7. TRINTELLIX $262 12 payments
  8. Azstarys $217 13 payments
  9. FANAPT $171 8 payments
  10. CAPLYTA $143 7 payments
  11. Other $2,095 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

5,284

Median for Psychiatry: 574

Drug cost

$428,048

Median for Psychiatry: $27,624

Branded share of claims

21.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 117 $137,939
Vraylar Cariprazine Hcl Brand 42 $70,363
Invega Sustenna Paliperidone Palmitate Brand 13 $49,010
Rexulti Brexpiprazole Brand 25 $39,543
Trintellix Vortioxetine Hydrobromide Brand 17 $14,700
Vyvanse Lisdexamfetamine Dimesylate Brand 27 $13,977
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 220 $7,896
Duloxetine Hcl Generic 466 $7,386
Lisdexamfetamine Dimesylate Generic 31 $7,267
Aripiprazole Generic 120 $6,956

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$161,672

Medicare's payments for the services billed

Medicare patients

243

Average age 73

Services billed

2,123

167 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 63%
Ischemic heart disease 44%
Chronic kidney disease 35%
Diabetes 30%
COPD 30%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $301
$301 — —
VRAYLAR
  • AbbVie, Inc. $150
$150 42 —
Azstarys
  • Corium, Inc. $97
$97 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $96
$96 117 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $58
  • Lundbeck LLC $37
$94 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record